Immunotherapy for the treatment of Alzheimer’s disease: amyloid-β or tau, which is the right target?

Diana L Castillo-Carranza1 Mitchell Center for Neurodegenerative Diseases, University of Texas Medical Branch, Galveston, TX, USA;2 Departments of Neurology, Neuroscience, and Cell Biology, University of Texas Medical Branch, Galveston, TX, USA

Marcos J Guerrero-Muñoz1 Mitchell Center for Neurodegenerative Diseases, University of Texas Medical Branch, Galveston, TX, USA;2 Departments of Neurology, Neuroscience, and Cell Biology, University of Texas Medical Branch, Galveston, TX, USA

Rakez Kayed1 Mitchell Center for Neurodegenerative Diseases, University of Texas Medical Branch, Galveston, TX, USA;2 Departments of Neurology, Neuroscience, and Cell Biology, University of Texas Medical Branch, Galveston, TX, USA;3 Sealy Center for Vaccine Development, University of Texas Medical Branch, Galveston, TX, USACorrespondence[email protected]

Citations (2)

Keep up to date with the latest research on this topic with citation updates for this article.

Immunotherapy for the treatment of Alzheimer’s disease: amyloid-β or tau, which is the right target?

Articles from other publishers (2)

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Immunotherapy for the treatment of Alzheimer’s disease: amyloid-β or tau, which is the right target?

Citations (2)

Articles from other publishers (2)

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date